Skip to main content

CVD Mortality Similar With Diuretic, ACE Inhibitor, or Calcium Channel Blocker

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 4, 2023.

By Elana Gotkine HealthDay Reporter

MONDAY, Dec. 4, 2023 -- For patients with hypertension and at least one other coronary heart disease risk factor, cardiovascular disease (CVD) mortality is similar for those receiving a thiazide-type diuretic, calcium channel blocker (CCB), or angiotensin-converting enzyme (ACE) inhibitor, according to a study published online Dec. 4 in JAMA Network Open.

Jose-Miguel Yamal, Ph.D., from The University of Texas Health Science Center at Houston, and colleagues randomly assigned participants aged 55 years or older with a diagnosis of hypertension and at least one other coronary heart disease risk factor to receive a thiazide-type diuretic (15,002), a CCB (8,898), or an ACE inhibitor (8,904). Participants were followed for all-cause mortality due to CVD, and a subgroup of 22,754 participants were followed for fatal or nonfatal CVD.

The researchers found that CVD mortality rates were 23.7, 21.6, and 23.8 per 100 persons in the diuretic, CCB, and ACE inhibitor groups, respectively, at 23 years after randomization. For most secondary outcomes, the long-term risks were similar among the three groups. The ACE inhibitor group had increased risks for stroke mortality and for combined fatal and nonfatal hospitalized stroke compared with the diuretic group (adjusted hazard ratios, 1.19 and 1.11, respectively).

"Angiotensin-converting enzyme inhibitors were associated with an increased risk of stroke outcomes (11 percent increased risk of combined fatal and nonfatal hospitalized stroke) compared with diuretics, and this effect persisted well beyond the trial period," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

Semaglutide Boosts Kidney Outcomes With Obesity + Cardiovascular Disease

TUESDAY, May 28, 2024 -- Once-weekly subcutaneous semaglutide shows a benefit for kidney outcomes in people with overweight or obesity and established cardiovascular disease...

Statins Reduce CVD Risk in Adults Aged 75 to 85 and 85 Years and Older

TUESDAY, May 28, 2024 -- For patients aged 75 years and older, statin therapy is associated with a risk reduction in cardiovascular diseases (CVDs), according to a study published...

Fish Oil Beneficial for Reducing Risk for Cardiovascular Disease Progression

WEDNESDAY, May 22, 2024 -- The role of regular use of fish oil supplements varies for people with and without cardiovascular disease, according to a study published online May 21...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.